Cubist Systematic Strategies, LLC Adc Therapeutics Sa Transaction History

Cubist Systematic Strategies, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.66 - $5.29 $200,486 - $638,899	120,775 New	120,775 $542,000
Q2 2023 Aug 14, 2023	BUY	$1.9 - $2.66 $4,542 - $6,360	2,391 Added 9.55%	27,437 $58,000
Q1 2023 May 15, 2023	SELL	$1.92 - $5.45 $3,052 - $8,665	-1,590 Reduced 5.97%	25,046 $48,000
Q4 2022 Feb 14, 2023	BUY	$2.87 - $5.24 $43,385 - $79,213	15,117 Added 131.24%	26,636 $102,000
Q3 2022 Nov 14, 2022	BUY	$4.66 - $10.31 $53,678 - $118,760	11,519 New	11,519 $56,000
Q4 2021 Feb 14, 2022	SELL	$19.29 - $31.51 $178,548 - $291,656	-9,256 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$20.45 - $30.0 $143,068 - $209,880	-6,996 Reduced 43.05%	9,256 $251,000
Q2 2021 Aug 16, 2021	BUY	$20.38 - $27.04 $331,215 - $439,454	16,252 New	16,252 $396,000

53.5M

28K

60.4K

Ticker ADCT
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,645,296
Market Cap $124M
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.